APA

Belhabri A., Thomas X., Wattel E., Chelghoum Y., Anglaret B., Vekhoff A., Reman O., Dombret H., Dhedin N., Michallet M., Fière D. & Archimbaud E. (20030725). All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial. : The hematology journal : the official journal of the European Haematology Association.

Chicago

Belhabri Amine, Thomas Xavier, Wattel Eric, Chelghoum Youcef, Anglaret Bruno, Vekhoff Anne, Reman Oumedaly, Dombret Hervé, Dhedin Nathalie, Michallet Mauricette, Fière Denis and Archimbaud Eric. 20030725. All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial. : The hematology journal : the official journal of the European Haematology Association.

Harvard

Belhabri A., Thomas X., Wattel E., Chelghoum Y., Anglaret B., Vekhoff A., Reman O., Dombret H., Dhedin N., Michallet M., Fière D. and Archimbaud E. (20030725). All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial. : The hematology journal : the official journal of the European Haematology Association.

MLA

Belhabri Amine, Thomas Xavier, Wattel Eric, Chelghoum Youcef, Anglaret Bruno, Vekhoff Anne, Reman Oumedaly, Dombret Hervé, Dhedin Nathalie, Michallet Mauricette, Fière Denis and Archimbaud Eric. All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial. : The hematology journal : the official journal of the European Haematology Association. 20030725.